TAVALISSE therapy requires vigilant monitoring for hypertension, hepatotoxicity, diarrhea, neutropenia, and embryo-fetal toxicity.

Key Safety Precautions in TAVALISSE Administration

Patients receiving TAVALISSE must undergo regular monitoring of blood pressure, liver function tests, and complete blood counts. Hypertension is a notable risk, necessitating frequent blood pressure assessments and management with antihypertensive agents as needed. Hepatotoxicity may manifest as elevated transaminases, requiring dose adjustment or discontinuation. Diarrhea and neutropenia are also significant risks, managed by supportive care and dose modification. TAVALISSE can cause fetal harm; effective contraception is advised for women of reproductive potential, and breastfeeding is contraindicated during and for one month after therapy.